ulcerative colitis

In its SEC filing, Seres Therapeutics Inc (NASDAQ: MCRB) disclosed it would not move forward with the planned SER-301 Phase 1b second study cohort. In its Q4 earnings release, Seres said that SER-301 was safe to proceed to the placebo-controlled second cohort in a Phase Ib trial...

Pfizer Inc (NYSE: PFE) has announced topline results from a Phase 3 study of etrasimod in moderately to severely active ulcerative colitis (UC).  In the study, etrasimod patients achieved statistically significant improvements in the primary endpoint of clinical remission at...

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), has announced results from the Phase 2b QUASAR Induction study of Tremfya (guselkumab) in active ulcerative colitis. The findings were presented at the Congress of the European Crohn's and Colitis...

Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab achieved statistically superior clinical remission rates at 12 weeks compared to placebo. The LUCENT-1 Phase 3 study of 1,162 patients included patients who...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers. Amilo-5MER is a synthetic peptide consisting of 5 amino acids that significantly reduces symptoms and histopathological hallmarks of Inflammatory bowel disease (IBD) in...

Seres Therapeutics Inc (NASDAQ: MCRB) announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study of SER-287 in patients with mild-to-moderate ulcerative colitis (UC).  In July, the Company posted the topline data readout, which noted that the SER-287 Phase...

The European Commission has approved Bristol Myers Squibb & Co's (NYSE: BMY) Zeposia (ozanimod) for ulcerative colitis (UC). The approval comes for adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to...

Less than a year ago, Ventyx Biosciences Inc (NASDAQ: VTYX) emerged from stealth mode, then last month, it sprinted to Wall Street with a $100 million IPO ticket. This week Ventyx nabbed an upsized $152 million by offering 9.5 million shares at $16, within the range of $15 to $...

Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to severe ulcerative colitis (UC). The study did not meet the primary efficacy endpoint of clinical remission at Week 12 nor secondary...

Kaleido Biosciences Inc (NASDAQ: KLDO) announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT), in mild-to-moderate ulcerative colitis (UC).  The study achieved the primary objective of safety and tolerability with...

Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC).  The analyses showed clinical benefits of continued dosing with filgotinib 200mg, an oral once-daily JAK1...

Eli Lilly And Co (NYSE: LLY) has posted new data from the Phase 2 study of mirikizumab in moderately to severely active ulcerative colitis (UC) patients. Related: Eli Lilly's Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year. Patients taking...

AbbVie Inc (NYSE: ABBV) has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for active ulcerative colitis to FDA and the European Medicines Agency (EMA). Related Content: FDA Hits JAK inhibitors With Heart...

Analysts have lowered the price target and downgraded Theravance Biopharma Inc (NASDAQ: TBPH) after disappointing ulcerative colitis Phase 2 trial data. Related: Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study Cowen downgraded Theravance Biopharma to Market...

Theravance Biopharma Inc's (NASDAQ: TBPH) Izencitinib, a "gut-selective" JAK inhibitor developed for ulcerative colitis and Crohn's disease, failed a key Phase 2 trial. Johnson & Johnson's (NYSE: JNJ) pharmaceutical unit Janssen dished out $100...